HUMAN MILK Oligosaccharides: Chemical Structure, Functions
And Enzymatic Synthesis

Hoang Anh Nguyen¹, Thu-Ha Nguyen², Dietmar Haltrich²

¹Department of Biochemistry and Food Biotechnology, Faculty of Food Science and Technology, Hanoi University of Agriculture, Hanoi, Vietnam; ²Food Biotechnology Laboratory, Department of Food Sciences and Technology, University of Natural Resources and Life Sciences Vienna, Austria

Email: hoanganhcntp@hua.edu.vn

Received date: 25.05.2012 Accepted date: 21.08.2012

ABSTRACT

Human milk is considered as the best form of nutrition for the first few months of human life. The part that contributes to the important function of human milk contains oligosaccharides which are not found in infant formulas. Human milk oligosaccharides (HMOs) are the third most abundant molecular species in human milk after lactose and fat and its amount approximates 15 g/L. To date, about 200 HMOs have been purified and their structures have been determined. Basic core structure of HMOs is lactose at the reducing end elongated by fucose, N-acetylglucosamine and sialic acid. HMOs are considered to be one of the most important growth factors for intestinal bifidobacteria, beneficial bacteria dominated in gastrointestinal tract of breast-fed infants, and potential inhibitors of adhesion of pathogenic bacteria to epithelial surfaces. For this reason, there is a continuous interest in finding structures as well as synthesis of HMOs by enzymatic method that can be applied for infant foods and drugs. This review focuses on structure and functions of HMOs, and enzymatic synthesis of some well known HMOs.

Keywords: Human milk oligosaccharides (HMOs), lactose, fucose, N-acetylglucosamine, probiotic

1. INTRODUCTION

Human gastrointestinal tract (GIT) comprises a healthy microbiota dominated by bifidobacteria (intestinal probiotic bacteria) that beneficially affect intestinal microbial balance through a variety of mechanisms (2005). Many attempts have been made to maintain adequate
amounts of probiotic bacteria in colon, and they must be taken in sufficient quantities (>1 x 10^10/day) (Duggan et al., 2002). Basically, there are two major strategies for stimulation of the growth and/or activity of the healthy promoting bacteria. One approach is supplement of living bacteria (probiotics) mostly of human origin (Bifidobacterium and Lactobacillus) to foods, which must survive the gastrointestinal tract and beneficially affect the host by improving its intestinal microbial balance. The second approach is supplement of non-digestible oligosaccharides (prebiotics) to foods which stimulate the growth and/or activity of one or number of heath promoting colon bacteria and thus improve host health (Gibson and Roberfroid, 1995). Probiotics, however, can not be used in a wide range of food products as they can not have long life in their active form. Currently, they are predominantly used in fermented dairy products that are required refrigeration to maintain the shelf life (Sangwan et al., 2011). Prebiotics can be applied in wide range of foodstuffs because of their known advantages: (i) They may be manufactured by extraction from plan sources, enzymatic synthesis and enzymatic hydrolysis of polysaccharides; (ii) Prebiotics are usually stable in the presence of oxygen, over a wide range of pH, temperature, and time, which is not the case for probiotics (Figueroa-Gonzalez et al., 2011).

In particular, many oligosaccharides have been commercially produced for functional foods (fermented milks and yogurts, baby foods, sugar free confectionary and chewing gum) such as inulin, fructo-oligosaccharides, galacto-oligosaccharides, xylo-oligosaccharides, isomalto-oligosaccharides, etc. (Figueroa-Gonzalez et al., 2011). However, there are still many remaining questions regarding the relation between the structures of non-milk-derived oligosaccharides and their biological functions. Whereas, HMOs have been wildly proved to putatively modulate the intestinal microbiota of breast-fed infants by acting as decoy binding sites for pathogens and as prebiotics for enrichment of beneficial bacteria (Marcobal et al., 2010). This work aims to review current knowledge about structures and functions of HMOs in the GIT of infants whose immune system is not perfectly developed, and continuous interest in finding enzymes that can be applied for HMOs production, especially in large-scale.

2. STRUCTURES, BIOSYNTHESIS AND FUNCTIONS OF HMOs

2.1. Infant microflora

Immediately after a human being is born, the breast-fed infant gastrointestinal tract is rapidly colonized by a microbial system often dominated by bifidobacteria. This microbial ecosystem consisting a wide range of bacteria commensally and pathogenically resides is called infant microflora (German et al., 2008). To prevent toxicity from pathogenic bacteria, the constant interaction between the host and beneficial bacteria in GIT is required. Beneficial strains may protect host from pathological bacteria through competition for binding sites or nutrients, production of inhibitory substances such as bacteriocin and organic acids (Claud and Walker 2001).

Bacterial diversity and density in the gut lumen increase from the upper (esophagus, stomach and duodenum) to the lower (small intestine, large intestine and anus) GIT, from an almost sterile content in the stomach to colon and faecal sample (Kelly et al., 2005). Once established, the adult human GIT remains stable and comprises more than 1000 billion bacteria with over 1000 different species (Dethlefsen et al., 2006). The number of microbial cells in gut lumen is about 10 times higher than the number of eukaryote cells in human body (Guarnier and Malagelada, 2003). In contrast, the infant GIT is more variable in its composition and less stable over time. The foetal GIT is sterile and bathed in swallowed amniotic fluid and rapidly colonized few days after birth. Bacterial diversity and density are influenced by factors such as mode of delivery,
the maternal microbiota, gestational age, the surrounding environment and antibiotic treatment, and especially infant’s diet (breast versus formula feeding). This change continues up to two years of age when microbiota stabilizes and resembles that of adult (Fanaro et al., 2003). The bacterial flora is usually heterogeneous during the first few days of life, independently of feeding habits, in the subsequent few days, the composition of the enteric microbiota of infant is strongly influenced by diet. Many studies have reported that bifidobacteria and lactobacilli are dominant in breast-fed infants, while formula feeding generally results in a more diverse microbial population such as E. coli, Clostridia and Staphylococci... (Martin et al., 2003; Sinkiewicz and Nordstrom, 2005). A diet of breast milk creates an environment favoring bifidobacteria in breast- fed neonates. By the end of first week, bifidobacteria represent 95% of total bacteria population in the faeces of exclusively breast-fed infants, whereas in formula-fed infants they form less than 70%, and by day 6 bifidobacteria in the GIT of breast-fed infants already exceeded enterobacteria by a ratio of 1000/1 (Yoshioka et al., 1983). Human breast milk is a significant source of commensal bacteria for infants’ GIT, contains up to $10^6$ microbes/L in a healthy mother (Moughan et al., 1992). The predominance of beneficial bacteria in the intestinal microbiota of breast- fed infants, can infer important health benefits to infants as well as health status in later life (Palmer et al., 2007).

2.2. Structures and biosynthesis of HMOs

HMOs are the third most abundant molecular species in human milk after lactose and fat and amount approximately 15g/L (Coppa et al., 1993). They are quantitatively higher than that of the most relevant domestic mammals’ milks by a factor of 10 to 100 (Boehm and Stahl, 2007). Currently, about 200 HMOs have been purified and determined. However, detailed structural identification of the HMOs is still lacking because of the complexity and the diversity of the structures (Rockova et al., 2011). Basically, most HMOs contain a lactose at the reducing end as the core structure, elongated by N-acetylglucosamine (GlcNAc), galactose (Gal), sialic acid (also known as N-acetylneuraminic acid; NeuAc), and fucose (Fuc) at non-reducing end with many and varied linkages between them. They range from three to ten monosaccharides in length (McVeagh and Miller, 1997). As an example, figure 1 indicates the structures of lacto-N-fucopentaose I, lacto-N-fucopentaose II and lacto-N-fucopentaose III.

Few unusual oligosaccharides found in human milk which do not contain the core structure, even without lactose at reducing end. The mechanism to produce these unusual oligosaccharides is yet unknown. They might be the products of unknown degradation from larger HMOs (Kobata, 2010). Due to structural complexity and variety, HMOs are resistant to enzymatic hydrolysis in upper gastrointestinal tract of host. This has been proved by Engfer and Gnoth with in vitro digestion studies in which they used human pancreatic juice and brush border membranes prepared from human or porcine intestinal tissue samples as enzyme sources (Engfer et al., 2000; Gnoth et al., 2000).

HMOs are produced with large amount in milk secreted at early stages of lactation in Golgi apparatus of cells lining the alveoli and smaller ductules. Alpha-lactalbumin firstly regulates enzyme galactosyltransferase to produce lactose in a reaction between UDP-galactose and glucose. The biosynthetic steps leading from lactose to HMOs are currently not clear (Bode, 2009). However, well known structures of HMOs (galactosyl, N- acetylgalactosaminy, fucosyl and sialyl) are supposed to form by concerted action of glycosyltransferases (Kobata, 2010). The elongation of lactose may start by the action of β- 3-N-acetyl-glucosaminyltransferase with an enzymatic transfer of N-acetyl glucosamine (GlcNAc) residue through β-1,3-linkage to the galactose (Gal) residue of lactose, followed by further addition of Gal through either β-1,3- or β-1,4 linkage to GlcNAc to create two major core
Human milk oligosaccharides: chemical structure, functions and enzymatic synthesis

Figure 1. Configuration of the isomeric lacto-N-fucopentaoses (I, II, III)
(adapted from Newburg DS, 2009)

HMOs content varies not only between duration of lactation, but also during infant's gestation, and with genetic makeup of the mother (McVeagh and Miller, 1997). Amount of HMOs is the highest in the newborn period, rising during the first 5 days and then reducing after the first 3 months (Viverge et al., 1990).

2.3. Functions of HMOs in infants

HMOs are considered as (i) the growth factors for intestinal bifidobacteria in breast-fed infants and (ii) potential inhibitors of adhesion of pathogens in infants' GIT to epithelial surfaces (Matsuo et al., 2003).

2.3.1. Growth factors for intestinal bifidobacteria in breast-fed infants

HMOs have been considered as sole carbon source (prebiotic) for fermentation of desired bacteria of breast-fed infants. In the presence of HMOs, the desired bacteria metabolize HMOs and the metabolites from degradation of HMOs...
serve not only as beneficial components such as short chain fatty acids for the growth of desired bacteria but also as growth inhibitors to undesired bacteria (Bode, 2009).

Many HMO molecules have been purified from human milk and used in vivo as sole carbon source for fermentation of bifidobacteria and lactobacilli. These analyses have shown that several bifidobacterial species can grow well on HMOs (Kiyohara et al., 2009; Marcobal et al., 2010; Rockova et al., 2011). In addition, amount of intact HMOs were found very low in the feces of term and preterm breast-fed infants (Sabharwal et al., 1988; Sabharwal et al., 1988). This postulates that a majority of HMOs reaches the large intestine, where they are preferably used as substrates for bifidobacteria. The function of HMOs for the enrichment of bifidobacteria has also been known when a study indicated the acidity level (metabolites from the fermentation of bifidobacteria) in feces of breast-fed babies is higher than that in feces of formula-nourished babies (Kobata, 2003). Moreover, a cluster of genes encoding for glycosidases (sialidase, fucosidase, N-acetyl-β-hexosaminidase, β-galactosidase), that cleave HMOs into its constituent monosaccharides, and HMO transporters have been found recently in the genome of Bifidobacterium longum subsp. infantis ATCC1569. They are likely linked to genomic mechanisms of milk utilization for infants’ bifidobacteria (Sela et al., 2008).

Even though HMOs have been considered as a sole carbon source for beneficial bacteria in GIT of infants, direct fermentation of HMOs by bifidobacteria as well as intestinal bacteria has been poorly investigated. Rockova and coworkers (2011) (Rockova et al., 2011) found a great variability of bifidobacteria in the ability to grow on HMOs. Bifidobacteria of human origin (Bifidobacterium bifidum, Bifidobacterium longum) have a better growth on human milk compared to those of animal origin (B.animalis). Ward and coworkers (2006) (Ward et al., 2006) pointed out that Bifidobacterium infantis fermented purified HMOs as a sole carbon source, while Lactobacillus gasseri, another gut commensal did not ferment HMO. These results support the hypothesis that HMOs selectively affect the commensal bacteria in the intestinal tract.

### 2.3.2. Potential inhibitors of pathogen adhesion

There are two possibilities proposed for potential inhibitors of pathogen adhesion (figure 2): (i) HMOs are soluble receptor analogues of epithelial cell-surface carbohydrates, and compete with epithelial ligands for pathogens by binding to proteins on the pathogens (lectins or haemmaglutinins); (ii) HMOs may also regulate gene expression related to enzymes change the cell-surface glycome which could interfere to adhesion, proliferation, and colonization of pathogens (Kunz and Rudloff, 1993; Bode, 2009).

To date, two types of HMOs mainly considered as potential inhibitors of pathogen adhesion, are fucosylated oligosaccharides and sialylated oligosaccharides. α1,2-Linked fucosylated HMOs (2'-fucosyllactose, and lacto-N-fucopentaose-I), most commonly found in mothers’ milk, express the inhibition with pathogens (Morrow et al., 2005). The reason for this is: α1,2-linked fucosylated HMOs are quite similar to HAB antigen motif, basis of the human ABO-histo-blood group system. The motif with terminal structure Fucα1-2Gal is H antigen, and H antigen is attached to GlcNAc with β1,3 and β-1,4-linkages to create H1 and H2 antigens, respectively. A and B antigens are formed by adding a Gal or N-acetyl-galactosamine (GalNAC) residue to the H antigen. ABH antigens are very abundant in red blood cells as well as intestinal epithelium for human immune system. In vitro tests indicated that 2'-fucosyllactose can adhere to Campylobacter jejuni, one of the major causes of diarrhea (Ruiz-Palacios et al., 2003; Morrow et al., 2005). Fucosyllated HMOs are also able to stop the binding of E.coli enterotoxin to the cells (Kunz and Rudloff, 1993). Sialylated oligosaccharides prevent the binding of E.coli strains associated with neonatal meningitis and sepsis (Kunz and Rudloff, 1993).
Figure 2. Anti-adhesive and glycome-modifying effects of HMOs (adapted from Bode L, 2009) “Most bacteria (commensals and pathogens) express glycan-binding proteins (lectins), that bind to glycans on the host’s epithelial cell surface (A), which is essential for bacteria to attach (a), and to proliferate and colonize the intestine (b). Some pathogens need to attach to the intestinal epithelial cell surface prior to invading the host (c). HMOs are structurally similar to the intestinal epithelial cell surface glycans. They can serve as bacterial lectin ligand analogs and block bacterial attachment (B). HMOs may also alter the intestinal epithelial glycosylation machinery and modify the cell-surface glycome (“glycocalyx”), which could impact bacterial attachment, proliferation, colonization (C)” (Bode 2009)

3. ENZYMATIC SYNTHESIS OF HMOs FOR APPLICATIONS IN FOODS AND DRUGS

Due to important biological functions, HMOs have attracted considerable interest. Many methods have been developed for the synthesis of HMOs that can be applied as ingredients in infant foods as well as drug development. In principle, HMOs can be synthesized by application of enzymes or by chemical approaches. However, great effort nowadays has been put into enzymatic methods, because chemical methods still require multiple steps to get rid of side products, and this complexity does not render chemical syntheses realistic for industrial applications (Scigelova et al., 1998). Enzymes used for synthesis of oligosaccharides can be either glycosyltransferases or glycosidases. However, currently enzymatic methods using glycosyltransferases are mostly used because of highly stereoselective and regioselective bond formation and no side products formed (Endo and Koizumi, 2000). Despite their recognized importance for infant health, synthesis of HMOs have been hindered by the fact that it is still very difficult to obtain large quantity of them by enzymatic synthesis (Chen et al., 2000). Wild type enzymes originated from plants and animals are difficult to obtain in large amount. Moreover, genes encoding for mammalian glycosyltransferases are difficult to be functionally expressed in E.coli. Thus, production of recombinant eukaryotic glycosyltransferases generally requires eukaryotic expression systems which often render the production tedious and expensive. These points limit the use of enzymatic methods for industrial production of oligosaccharides (Matsuo et al., 2003). By contrast, cloning and expression of bacterial glycosyltransferase genes in E.coli is much more convenient and efficient. Recently, the use of metabolically engineered bacteria to over-express heterologous glycosyltransferase and glycosidase genes is a powerful new technique.
that makes the production of HMOs in large amount with lower cost feasible. Using of whole cells or glycosyltransferases isolated from engineered microorganisms as the enzyme sources may open the way to produce HMOs at commercial scale that had been not yet successful. (Endo and Koizumi, 2000; Schwab and Gaenzerle, 2011).

Generally, the steps for enzymatic synthesis of HMOs using metabolically engineered E.coli are the following: (1) designate a β-galactosidase-negative (lacZ) E.coli strain in which a lacY gene encoding for β-galactoside permease still remains; (2) transform the genes encoding for glycosyltransferases that use lactose as acceptor to the above strain; (3) cultivate this strain at high cell density on alternative carbon source, such as glycerol, under the conditions that allow both glycosyltransferase and β-galactoside permease genes express; (4) feed the culture with lactose that should be actively internalized by the permease and glycosylated by the transferase; (5) purify and structurally characterize HMOs by chromatography and NMR (Priem, et al., 2002). This section focuses on the syntheses, which could be promising for the applications in large scale production, of some well known HMOs (Table 1).

### 3.1. N-acetyloligosaccharides

HMOs containing GlcNac (the bifidus factor) are necessary for the growth of bifidobacteria. These oligosaccharides form precursors in the biosynthesis of muramic acid, a component of the bacterial cell wall (McVeagh and Miller, 1997). Reports, to date, have indicated that N-acetylgligosaccharides of HMOs can be produced by N-acetylglucosaminyltransferases, β-N-acetylmuraminidases (β-N-acetylglucosaminidases/β-N-acetylmuraminidases or β-N-acetylmuraminidases) or β-galactosidases.

Blixt and coworkers (1999) have over-expressed the Neisseria meningitidis lgtA gene encoding for β-1,3-N-acetylglucosaminyltransferase (β-1,3-

<table>
<thead>
<tr>
<th>Table 1. HMOs mentioned in this review</th>
<th>Abbreviation</th>
<th>Structures</th>
</tr>
</thead>
<tbody>
<tr>
<td>N-acetyl oligosaccharides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lacto-N-biose I</td>
<td>LNB</td>
<td>Gal-β,1,3-GlcNAc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GlcNAc-β,1,3-Gal</td>
</tr>
<tr>
<td>N-acetyllactosamine</td>
<td>LacNAc</td>
<td>Gal-β,1,4-GlcNAc</td>
</tr>
<tr>
<td></td>
<td>Allo-LacNAc</td>
<td>Gal-β,1,6-GlcNAc</td>
</tr>
<tr>
<td>Lacto-N-triose</td>
<td>LNT-2</td>
<td>GlcNAc-β,1,3-Gal-β,1,4Glc</td>
</tr>
<tr>
<td>Lacto-N-neotetraose</td>
<td>LNNT</td>
<td>Gal-β,1,4-GlcNAc-β,1,3-Gal-β,1,4-Glc</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gal-β,1,4-Gal-β,1,4-GlcNAc</td>
</tr>
<tr>
<td>Sialylated oligosaccharides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>α 2,3-sialylactose</td>
<td>3'SL</td>
<td>Neu5Ac-α,2,3-Gal-β,1,4-Glc</td>
</tr>
<tr>
<td>α 2,6-sialylactose</td>
<td>6'SL</td>
<td>Neu5Ac-α,2,6-Gal-β,1,4Glc</td>
</tr>
<tr>
<td>Fucosyloligosaccharides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2'-fucosylactose</td>
<td>2FL</td>
<td>Fuc-α,1,2-Gal-β,1,4-Glc</td>
</tr>
<tr>
<td>Lacto-N-neo-fucopentaose-1</td>
<td>LNF-1</td>
<td>Fuc-α,1,2-Gal-β,1,4-GlcNAc-β,1,3-Gal-β,1,4-Glc</td>
</tr>
<tr>
<td>Lacto-N-neo-fucopentaose</td>
<td>LNNFP</td>
<td>Gal-β,1,4-GlcNAc-β,1,3-Gal-β,1,4-(Fuc-α,1,3)-Glc</td>
</tr>
<tr>
<td>Lacto-N-neodifucohexaose</td>
<td>LnNDFH</td>
<td>Gal-β,1,4-(Fuc-α,1,3)-GlcNAc-β,1,3-Gal-β,1,4-(Fuc-α,1,3)-Glc</td>
</tr>
<tr>
<td>Lacto-N-neodifucooctaose</td>
<td></td>
<td>Gal-β,1,4-GlcNAc-β,1,3-Gal-β,1,4-(Fuc-α,1,3)-GlcNAc-β,1,3-Gal-β,1,4-(Fuc-α,1,3)-Glc</td>
</tr>
</tbody>
</table>

* GlcNAc; N-acetylglucosamine, Gal; galactose, Glc; glucose, Neu5Ac; N-acetylneuraminic acid, Fuc; fucose
GlcNAcT) in E. coli. Characterization of the recombinant enzyme indicated that this enzyme is capable to catalyze the transfer of GlcNAc from UDP-GlcNAc in a β-1,3 linkage to acceptor (Gal residues) to create oligosaccharides with GlcNAc-β-1,3-Gal linkage (Blixt et al., 1999). Johnson and coworkers (1999) have developed enzyme-based technologies to successively synthesize several relevant HMOs using cloned bacterial glycosyltransferases (β-1,3-GlcNAcT; β1,4-galactotransferase (β-1,4-GalT); and α2-trans-sialidase). In the first step, they successfully scaled up and produced 250 grams of LNT-2 (GlcNAc-β-1,3-Gal-β-1,4Glc) from 100 L reactor containing lactose, UDP-GlcNAc and β-1,3-GlcNAcT, and then in the second step more than 300 grams of lacto-N-neotetraose (LNNtT; Gal-β-1,4-GlcNAc-β-1,3Gal-β-1,4Glc) were formed from 100 L reactor containing LNT-2, UDP-Gal and β-1,4-GalT (Johnson, 1999).

However, these methods still require nucleotide substrates. Liu and coworkers (2003) have co-expressed 4 enzymes (sucrose synthase (SusA); UDP-Glc-4-epimerase (GalE); β-1,4-GalT; α-1,4-galactotransferase (α-1,4GalT) in a single genetically engineered E.coli strain with high level of UTP production. SusA catalyzes the cleavage of sucrose to UDP-glucose and fructose. UDP-glucose is converted into UDP-galactose by GalE, and then β-1,4-GalT transfers galactose from UDP-galactose to acceptor (GlcNAc) to form N-acetyllactosamine (LacNAc, Gal-β-1,4-GlcNAc). LacNAc is then combined with an additional galactosyl by α-1,4GalT, resulting in the synthesis of 5.4 g of Gal-α-1,4-Gal-β-1,4-GlcNAc in 200ml reaction volume with 67% yield based on the consumption of GlcNAc (Liu et al., 2003).

A new fermentation process allowing large-scale production of HMOs by metabolically engineered bacteria has been reported by Priem and coworkers (2002). A β-galactosidase - negative (LacZ) E.coli strain carrying IgtA gene from Neisseria meningitides was cultivated at high density with glycerol as the sole carbon source using classical fed-batch strategy. This fermentation resulted in over-expression of IgtA and the synthesis of 6 g L⁻¹ of expected extracellular trisaccharide LNT-2 by β-1,3-GlcNAcT transfers GlcNAc to lactose. When IgtB gene encoding for the β-1,4-GalT from Neisseria meningitides was co-expressed with IgtA, LNT-2 was further converted to lacto-N-neotetraose (Gal-β-1,4-GlcNAc-β-1,3-Gal-β-1,4-Glc). However, for this co-expression, glucose instead of glycerol has to be used as sole carbon source for cultivation, and the product mainly remained intracellular (Priem et al., 2002).

β-N-acetylmuramidases (EC 3.2.1.52) are glycoside hydrolases, like typical exo-enzymes. Some of them (mostly from fungi) not only can cleave the terminal β-D-GlcNAc and β-D-GalNAc residues in N-acetyl-β-D-hexosaminides, but also can then transfer β-D-GlcNAc and β-D-GalNAc residues to broad variety of glycosidic and non-glycosidic acceptors (Slamova et al., 2010). N-acetyl-β-D-hexosaminides are easily obtained from hydrolysis of chitin, a second most abundant polysaccharide in nature after cellulose, using chitinases (Lee et al., 2007). Thus, the promising strategy is finding suitable β-N-acetylmuramidases that can be applied to produce HMOs using N-acetyl-chioliogosaccharides, products of chitin degradation, as donors. This would enable the use of low cost and easily available starting materials for the large-scale synthesis of novel oligosaccharides. To date, this strategy has been successfully used for activated substrates (derivatives of GlcNAc or N-acetyl-chitooligosaccharides), however it is not yet applied for food applications and large scale production because of toxicity and high cost (Singh, et al., 1997; Kurakake et al., 2003; Weignerova et al., 2003).

Matsuo and coworkers (2003) have used recombinant β-N-acetylgulosaminidases from Aspergillus oryzae to produce HMOs by reverse hydrolysis reaction, but the yield was very low with only 0.21 % of LNT-2 and 0.15% of its isomer (GlcNAc-β-1,6-Gal-β-1,4-Glc) (Matsuo et al., 2003).
Recently, enzyme β-galactosidase from Bacillus circulans was found that can hydrolyze lactose (donor) and then transfer galactosyl products to receptors (GlCNAC or GalNAc) (Sakai et al., 1992; Usui et al., 1996; Hernaiz and Crout 2000; Li et al., 2010). Some N-acetylgalactosaminide have been produced, such as Gal-β-1,4-GlcNAc with yield of 23.2% (Sakai et al., 1992), a mixture of LacNAc, allo-LacNAc (Gal-β-1,6-GlcNAc), Gal-β-1,4-Gal-β-1,4-GlcNAc, and Gal-β-1,4-Gal-β-1,4-Gal-β-1,4-GlcNAc with ratio of 28.75%, 2.29%, 9.47%, 5.67%, respectively (Li et al., 2010).

3.2 Sialylated oligosaccharides

Human milk, containing more than three times of sialylated oligosaccharides compared to cow′ milk, is an important source of sialic acids for breast-fed infants. Sialylated oligosaccharides are used for biosynthesis of mucins, glycoproteins and gangliosides which are concentrated in plasma membranes of nerve cells (McVeagh and Miller, 1997; Wang et al., 2001). Sialylated oligosaccharides are also known to have both anti-infective and immunostimulating properties (Boehm and Stahl, 2007). Sialylated HMOs, believed to protect breast-fed infants from infection, consist of N-acetylgalactosaminide (NeuAc) attached to Gal through α-(2,3) or α-(2,6) linkage.

From general principle of sialyllactose biosynthesis (figure 3), Gilbert and co-workers (1997) have characterized the gene encoding for α-2,3-sialyltransferase from Neisseria meningitides (Gilbert et al., 1997), then fused it with gene encoding for CMP-NeuAc synthetase and expressed in E.coli. The fusion protein was used to produce α-2,3-sialyllactose at the 100 g scale using a sugar nucleotide cycle reaction, starting from lactose, sialic acid, phosphoenolpyruvate and catalytic amounts of ATP and CMP. However, this method requires expensive substrates, thus it is not applicable for large scale. To solve this drawback, permeabilized and alive whole E.coli cells have been used.

Endo and coworkers (2000) (Endo et al., 2000) have developed a large-scale production of cytidine 5'-monophospho-N-acetylgalactosaminide acid (CMP-NeuAc) and sialylated oligosaccharides through a combination of recombinant E.coli strains and Corynebacterium ammoniagenes (bacterial coupling). The CMP-NeuAc production system consisted of Corynebacterium ammoniagenes having strong activity to convert orotic acid to UTP, and two recombinant E. coli strains over-expressing the genes encoding for CTP synthetase and CMP-NeuAc synthetase. When E. coli cells with over-expressed gene encoding for α-2,3-sialyltransferase from Neisseria gonorrhoeae were used for the CMP-NeuAc production system, 33 g/L of 3'-sialyllactose were produced after 11 h of reaction starting with orotic acid, NeuAc and lactose (Endo et al., 2000). In this system the activated sialic acid donor (CMP-Neu5Ac) was generated from exogenous sialic acid, which was transported into the cells by the permease NanT. Thus the disadvantage of this method is that it still requires an expensive compound (sialic acid).

To avoid this drawback, recently, Fierfort and coworkers (2008) and Drouillard and coworkers (2010) have successfully developed a microbiological process to economically produce 3'-sialyllactose (Fierfort and Samain, 2008) and 6'sialyllactose (Drouillard et al., 2010), respectively, without any exogenous supply (Figure 3). These strains co-expressed the α-2,3-sialyltransferase gene from Neisseria meningitides, or α-2,6-sialyltransferase gene from Photobacterium sp. J T-ISH-224 with the neuC, neuB and neuA Campylobacter jejuni genes encoding N-acetylglucosamine-6-phosphate-epimerase, sialic acid synthase and CMP-Neu5Ac synthetase, respectively. The concentration of 3'-sialyllactose and 6'sialyllactose (Gibson et al., 2005) obtained from long term high cell density culture with a continuous lactose feed were 25 g/L and 30 g/L, respectively. This method is highly promising for the production of sialyllactose at commercial scale.
**Figure 3. Engineered metabolic pathway for the production of 6′-sialyllactose** (Adapted from Drouillard, 2010) "Over-expressed heterologous genes are in bold. Discontinued arrows represent the enzymatic activities that have been eliminated. Lactose is internalized by lactose permease and sialylated by recombinant α-2,6-sialyltransferase using CMP-Neu5Ac produced from UDP-GlcNAc by the successive action of the N-acetylglucosamine-6-phosphate-epimerase NeuC, the sialic acid synthase NeuB, and the CMP-Neu5Ac synthetase NeuA. The β-galactosidase gene lacZ was knocked out to prevent lactose hydrolysis and the nanA and nanK genes were knocked out to prevent the formation of futile cycles in the CMPNeu5Ac biosynthesis pathway.”

3.3. Fucosyloligosaccharides

Enzymatic synthesis of fucose-containing oligosaccharides such as ABH and Lewis antigens has long been achieved (Kameyama et al., 1991; Murata et al., 1999; Zeng et al., 1999). However, the cost of synthesis substrates (GDP-β-L-fucose, p-nitrophenyl α-L-fucopyranoside) used by fucosyltransferase, is a limiting factor for large scale applications. To overcome this disadvantage, several studies have focused on the way to produce metabolically engineered E. coli containing fucosyltransferase that can be applied for production of fucosyloligosaccharides (Dumon et al., 2001; Drouillard et al., 2006).

Based on the biosynthesis mechanism of GDP-fucose in both prokaryote and eukaryotes (Stevenson et al., 1996; Andrianopoulos et al., 1998) (Figure 4 A), Dumon and coworkers (Dumon et al., 2001) have designated an engineered E. coli strain which is capable of overproducing GDP-fucose by inactivation of the gene wcj involved in colonic acid synthesis and over-expression of RcsA, a positive regulator of the colonic acid operon. The gene fucT encoding for α-1,3 fucosyltransferase from Helicobacter pylori then has been successfully co-expressed with IgG and IgB gene encoding for β1,3-GlcNAc-transferase and β1,4-galactotransferase of Neisseria meningitides, respectively. When this engineered E. coli strain is cultivated in medium containing lactose, the obtained fucosyloligosaccharides are lacto-N-neo-fucopentaose (LNnFP; Galβ1-4Glc-β1-3Galβ1-4(Fuc-α1,3)-Glc) and two...
oligosaccharides carrying Le\textsuperscript{a} motif: lacto-N-neofucohexaose (LNDFH, Gal-β-1,4-(Fuc-α-1,3)-GlcNAc-β-1,3-Galβ-1,4-(Fuc-α-1,3)-Glc), lacto-N-neofucooctaose (Gal-β-1,4-GlcNAc-β1,3-Gal-β-1,4-(Fucα-1,3)-Gal, β1,3-Galβ-1,4-(Fucα-1,3)-GlcNAc-β-1,3-Galβ-1,4-(Fucα-1,3)-Glc). The main product, LNnFP (~80% of total fucosylated fraction) was approximately 3 g L\textsuperscript{-1}.

Similarly, Drouillard and co-workers (Drouillard et al., 2006), later on, have developed an efficient method for production of H-antigen oligosaccharides: fucosyl α1,2-linked oligosaccharides (lacto-N-neofucopentaose-1; Fuc-α-1,2-Galβ-1,4-GlcNAc-β-1,3-Galβ-1,4-Glc; and 2'-fucosyllactose; Fucα-1,2-Galβ-1,4-Glc) by a metabolically engineered E.coli strain (Drouillard, Driguez et al., 2006) (figure 4B). The plasmid pET21a carrying futC gene encoding for α1, 2-fucosyltransferase and the plasmid pLNTR carrying IgTAB and rcsA genes encoding for β1,3-GlcNAc-transferase; β1,4-galactotransferase and a positive regulator of the colonic acid operon for synthesis of GDP-fucose, respectively, were co-transformed in this E.coli strain. This metabolically engineered E.coli strain was then grown with glucose as a carbon source, and fed with lactose as a receptor. Three grams of a mixture of 2'-fucosyllactose and lactoN-neofucopentaose-1 (in the ratio 23:57), was produced from 1 L culture (5 g L\textsuperscript{-1} lactose). Yield of lacto-N-neofucopentaose-1 can be improved by delaying activity of futC until Galβ-1,4-GlcNAc-β-1,3-Galβ-1,4-Glc is synthesized in large amount (figure 4B).

4. CONCLUSION

HMOs are the third most abundant molecular species in human milk after lactose and fat. Structure of HMOs contains lactose at reducing end elongated with N-acetylglucosamine, L-fucose and N-acetyl neuraminic acid. Even though 200 HMOs are
currently determined, detail structural identification of the HMOs is still lacking because of the complexity and diversity of the structures. Two potential properties of HMOs, which are as the "growth factors for intestinal bifidobacteria in breast-fed infants" and the "inhibitors of adhesion of pathogens" have been well documented. Therefore, many HMOs are of interest for applications in infant foods as well as drug development. These HMOs have been produced by enzymatic method mostly using glycosyltransferases, and especially the approaches using metabolically engineered bacteria allow the production of HMOs in large scale. However, a suitable approach for a commercial scale production of HMOs, that has not yet been successful, is of a continuous interest.

REFERENCES


